Liu has also cofounded six biotechnology and therapeutics companies, including Editas Medicine, Beam Therapeutics, Pairwise Plants and Exo Therapeutics. Base editing, phage-assisted continuous evolution (PACE) and DNA-encoded libraries are three technologies pioneered in his laboratory that are now widely used in the biomedical sciences. Liu's major research interests include development and use of genome editing technologies to study and treat genetic diseases the evolution of proteins with novel therapeutic potential and the discovery of bioactive synthetic molecules using DNA-encoded libraries. He has published more than 170 papers and is an inventor on more than 65 issued US patents. As a professor at Harvard and the Broad Institute, Liu integrates chemistry and evolution to illuminate biology and develop next-generation therapeutics. Liu initiated the first general effort to expand the genetic code in living cells. During his PhD research at Berkeley, David R.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |